Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.
The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders.